Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification.
One main pathophysiological mechanism underlying the increased risk for uric acid nephrolithiasis in humans with the metabolic syndrome is the excretion of unduly acidic urine, in part because of reduced excretion of the main urinary buffer, ammonium. The Zucker diabetic fatty (ZDF) rat, an established rodent model of the metabolic syndrome, has similar urinary abnormalities, attributed in part to lower expression and activity of the principal mediator of proximal tubule ammonium excretion, brush-border membrane Na+/H+ exchanger 3 (NHE3). These defects are associated with renal tubular steatosis in ZDF rats, but the causal relationship between renal steatosis and defective urinary acidification has not been investigated in vivo. We hypothesized that reduction of renal steatosis would commensurately normalize urinary acidification parameters. We treated ZDF rats with thiazolidinediones to reduce nonadipose tissue steatosis. Four weeks of treatment reduced renal triglyceride accumulation and restored urinary acidification parameters in ZDF rats to levels comparable to their lean littermates; urinary acidification was not affected by treatment in lean rats. To further document the direct effects of fat, we showed that functional abnormalities induced by fat loading in a cell culture model of proximal tubule steatosis and lipotoxicity can be reversed by fat removal but not by thiazolidinediones alone. Together, these findings support the causative role of renal steatosis in the pathogenesis of urinary acidification defects, demonstrate reversibility upon lipid removal, and highlight a potential therapeutic strategy for renal abnormalities in the metabolic syndrome.
Bobulescu
I Alexandru
IA
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8856, USA.
Dubree
Michele
M
Zhang
Jianning
J
McLeroy
Paul
P
Moe
Orson W
OW
D000143:Acids / Q000652:urine*; D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D005230:Fatty Acids, Nonesterified / Q000097:blood; D007668:Kidney / Q000378:metabolism*; D007687:Kidney Tubules, Proximal / Q000378:metabolism*; D008871:Microvilli / Q000378:metabolism; D009893:Opossums; D047495:PPAR gamma / Q000819:agonists; D051381:Rats; D011924:Rats, Zucker; D000074083:Sodium-Hydrogen Exchanger 3; D017923:Sodium-Hydrogen Exchangers / Q000378:metabolism*; D045162:Thiazolidinediones / Q000494:pharmacology; D014280:Triglycerides / Q000378:metabolism*
D000143:Acids; D005230:Fatty Acids, Nonesterified; D047495:PPAR gamma; C000613385:SLC9A3 protein, human; C000613387:Slc9a3 protein, rat; D000074083:Sodium-Hydrogen Exchanger 3; D017923:Sodium-Hydrogen Exchangers; D045162:Thiazolidinediones; D014280:Triglycerides
J Lipid Res. 2005 Jun;46(6):1295-302
15772429
J Am Soc Nephrol. 2006 Jul;17(7):2026-33
16775030
Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E216-21
15367397
J Biol Chem. 1957 May;226(1):497-509
13428781
J Hum Hypertens. 2003 Jan;17(1):7-12
12571611
N Engl J Med. 2004 Sep 9;351(11):1106-18
15356308
Pflugers Arch. 2009 May;458(1):5-21
18853182
Kidney Int. 2004 Apr;65(4):1422-5
15086484
J Am Soc Nephrol. 1999 Nov;10(11):2412-25
10541303
Am J Kidney Dis. 2006 Dec;48(6):905-15
17162145
J Clin Invest. 1996 Nov 15;98(10):2381-7
8941657
J Clin Invest. 1988 Jan;81(1):159-64
3121674
Annu Rev Physiol. 2005;67:573-94
15709971
Am J Physiol Renal Physiol. 2005 Oct;289(4):F685-91
15942046
Am J Physiol. 1997 Oct;273(4):E708-13
9357799
Annu Rev Med. 2002;53:319-36
11818477
Am J Physiol. 1981 Nov;241(5):C220-6
6272583
Drug Metab Dispos. 2000 Jul;28(7):772-80
10859151
Kidney Int. 2006 Feb;69(3):440-9
16514429
Metabolism. 1967 Feb;16(2):176-88
6018961
Diabetes. 1995 Aug;44(8):863-70
7621989
Proc Soc Exp Biol Med. 1983 May;173(1):68-75
6344096
Kidney Int. 2006 Nov;70(9):1560-6
16955100
Am J Physiol Renal Physiol. 2005 Aug;289(2):F442-50
15814531
Diabetes. 1988 Aug;37(8):1020-4
3292322
Kidney Int. 2007 Dec;72(11):1367-73
17805239
Kidney Int. 2007 Mar;71(6):504-13
17228368
Am J Nephrol. 2006;26(3):245-57
16757903
J Am Soc Nephrol. 2004 Nov;15(11):2775-91
15504931
J Clin Invest. 1991 Nov;88(5):1703-8
1658050
J Am Soc Nephrol. 1991 May;1(11):1193-203
1932632
Am J Physiol. 1989 Apr;256(4 Pt 2):F672-9
2539748
Am J Physiol Renal Physiol. 2008 Jun;294(6):F1315-22
18417539
N Engl J Med. 2006 Nov 30;355(22):2297-307
17135584
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Mar 5;801(2):265-72
14751795
Am J Kidney Dis. 1989 Oct;14(4):258-61
2679054
J Clin Invest. 1962 Mar;41:537-42
14036165
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1784-9
10677535
J Clin Invest. 2000 Jul;106(2):171-6
10903330
Kidney Int. 2002 Sep;62(3):971-9
12164880
Diabetes Obes Metab. 2003 Jul;5(4):234-43
12795656
Am J Physiol Cell Physiol. 2004 Jul;287(1):C64-72
14973148
Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E729-37
12217890
Clin J Am Soc Nephrol. 2007 Sep;2(5):883-8
17702734
Am J Physiol Renal Physiol. 2008 Oct;295(4):F1071-81
18667486
Clin J Am Soc Nephrol. 2007 May;2(3):550-62
17699463
Kidney Int. 2001 Aug;60(2):757-61
11473659
Curr Opin Lipidol. 2003 Jun;14(3):281-7
12840659
FASEB J. 2001 Feb;15(2):312-21
11156947
J Am Soc Nephrol. 2006 May;17(5):1422-8
16597681
J Nutr Sci Vitaminol (Tokyo). 1992 Oct;38(5):517-21
1294711
Am J Physiol. 1995 Jun;268(6 Pt 2):F1177-84
7611458
Am J Physiol Endocrinol Metab. 2005 May;288(5):E930-4
15632102
Diabetes. 2004 Aug;53(8):2169-76
15277403
Am J Physiol. 1982 Jun;242(6):F733-9
6283903